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Abstract 
Background: Synthetic cannabinoids (SCs), are typically full agonists at the cannabinoid CB1 receptor, 
therefore considerably more potent than natural cannabis (NC) and may have correspondingly more serious 
psychological effects. Despite government sanctions against their production they continue to be available 
in ever-increasing varieties over the internet. Psychological consequences of SC use are relatively 
unknown. Aim: To synthesise the available research on the psychological consequences of SC use. Method: 
A literature search of three databases was conducted in February 2018, including the following keywords: 
Spice, synthetic cannabis, cognition, affect, behaviour, psychosis, depression and anxiety. Results: 
Seventeen papers involving a variety of participants were eligible for inclusion: one controlled 
administration study, seven cross-sectional studies, five internet surveys and four qualitative studies.  The 
controlled administration study showed that, compared to placebo SCs acutely affected some aspects of 
cognitive functioning and subjective psychological ratings. Non-controlled, cross-sectional studies 
generally showed that SC users performed lower on cognitive tasks and showed elevated symptomatology 
(e.g. paranoia) compared to both NC and non-cannabis users. Methodological limitations were noted across 
different study designs. There is limited research on how doses, frequency, or type of SC influence 
outcomes. Conclusions: Acutely SC use can result in a range of psychological outcomes, and when non-
intoxicated SC users appear to differ from NC and non-users on various affective and cognitive domains. 
As SC use is increasing in at-risk populations there is an urgent need for more and better research to inform 
users, professionals and policymakers. 
Keywords: Synthetic cannabis, psychological, behavioural, affective, cognitive, depression, anxiety, 
systematic review 
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Introduction 
Synthetic cannabinoids (SCs) were first developed in the 1960s as researchers explored potential medical 
uses of compounds that targeted cannabinoid (CB1) receptors (Sedefov et al., 2009) . Over the past ten 
years SCs have been used recreationally and 179 different SC compounds have now been notified to the 
European Monitoring Centre of Drugs and Drug Addiction (EMCDDA, 2018).  Common street names for 
these drugs include ‘spice’ or ‘K2’. Despite the overall prevalence of SC use being relatively low (Van 
Amsterdam et al., 2013),  their use by more marginalised social groups, such as homeless and prison 
populations (EMCDDA, 2018) is a concern.   For example, a UK survey of 8 prisons reported the prevalence 
of ‘spice’ use within the previous month had increased from 10% in 2015 to 33% in 2016, with 46% of 
those users using almost daily (EMCDDA, 2017). 
Effects of synthetic cannabis use 
Whereas 9-tetrahydrocannabinol (THC), the main psychoactive component of natural cannabis (NC)), is 
a partial agonist  at the cannabinoid receptors CB1 and CB2, most SCs act as full agonists at CB1 and are 
therefore much more powerful (Auwärter et al., 2009; EMCDDA, 2011) with a 4-5 times higher affinity 
(ElSohly et al., 2014) and a 40-660 times higher potency than THC (Van Amsterdam et al., 2015). It has 
therefore been suggested that the adverse side effects induced by SCs may be much more severe and occur 
more frequently than those induced by NC (Albertson et al., 2016; D’Souza et al., 2016; Gray et al., 2016; 
Van Amsterdam et al., 2015).  In the media and online, it has been reported anecdotally that users appear  
like ‘zombies’ who can be seen staggering around unresponsive to the environment following SC use 
(Cooke and Birchall, 2018). To date, clinical research into the effects of SCs remains in its infancy with the 
literature consisting mainly of uncontrolled studies for both ethical and practical reasons.  
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Adverse physical health effects have been identified following SC use, including tachycardia, myocardial 
infarction, acute kidney injury, seizures and gastrointestinal problems evidenced from a mixture of case-
reports and retrospective case note reviews (see Karila et al., 2016, Tait et al., 2016 and Weinstein et al., 
2017 for reviews). A small number of case series have been published on the effects of SC on driving, 
including poor coordination, sedating effects, confusion and impairment of motor skills (Musshoff et al., 
2014; Yeakel and Logan, 2013). In addition to these risks, prolonged use of SCs has been associated with 
withdrawal symptoms including agitation, anxiety and mood swings (Nacca et al., 2013). Fatalities have 
also been documented, with Tait et al., (2016) identifying at least 26 individuals who died following SC 
use. Potential mechanisms have included cardiac dysrhythmias or seizures, liver and kidney failure as well 
as indirect causes such as hypothermia (people found unconscious outdoors in winter); and jumping from 
a building (Tait et al., 2016). The current review focuses primarily on mental health. 
Alongside increases in recreational SC use, there has been a surge of case reports of individuals with no 
pre-existing mental health conditions experiencing acute psychotic reactions as well as anxiety, suicidality 
and other adverse psychological reactions to SC use (see Cohen and Weinstein, 2018, Papanti et al., 2013, 
Karila et al., 2016 and Tait et al., 2016 for reviews). In some cases, these have resolved quickly with 
minimal intervention, in others, there have been persistent difficulties (Müller et al., 2010, 2016; Van der 
Veer and Friday, 2011; Wilkinson et al., 2014). Attempts to conduct larger scale research investigating 
these effects have mainly come from retrospective reviews of data from toxicology reports or poison hotline 
databases (Doğan et al., 2016; Forrester, 2011; Hermanns-Clausen et al., 2013, 2017; Hoyte et al., 2012; 
Waugh et al., 2016). This research has evidenced a wide range of adverse psychological symptoms 
including agitation, hallucinations and confusion.  For example, a review in 2013 reported that increasing 
numbers of cases of acute psychosis following SC use, dubbed ‘Spiceophrenia’, were occurring (Papanti et 
al., 2013). 
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There is also evidence of worsening of mental health difficulties in individuals with pre-existing conditions. 
This comes from a mixture of case-studies (Celofiga et al., 2014; Leibu et al., 2013 for example) and 
retrospective case note reviews from records in psychiatric inpatient settings (Bassir Nia et al., 2016; 
Manseau et al., 2017; Shalit et al., 2016 for example). These indicate acute psychiatric symptomatology, in 
some cases requiring intervention, ranging from sedation to ECT and hospitalisation. The severity of 
psychiatric symptoms has been observed to be greater than that from  NC user (Bassir Nia et al., 2016; 
Pereira et al., 2016; Shalit et al., 2016).  
Given the potential of SCs to impact on the mental health of users, we carried out a systematic review of 
the existing literature to address the question: What are the psychological effects of SC use? 
Method 
Search Strategy 
A search strategy was used to identify the relevant studies from the following electronic databases: 
 Medline (1961 – February 2018) 
 Cumulative Index to Nursing and Allied Health (CINAHL) (1904 – February 2018) 
 PsycInfo (1806 – February 2018) 
The search terms consisted of two main concepts, synthetic cannabinoids and psychological outcomes.  The 
following keywords related to synthetic cannabinoids were used in the searches:  
Spice OR K2 OR synthetic cannabis OR synthetic marijuana OR legal marijuana OR JWH 
The following keywords related to psychological outcomes were used: 
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Psychological OR Psychiatric OR Cognition OR Neurocognition OR Affect OR Mood OR Behaviour OR 
Mental health OR Psychosis OR Schizophrenia OR Paranoia OR Hallucination OR Anxiety OR Panic OR 
Depression.  
The syntax was amended to include functions such as * to allow for variations of forms of words to be 
searched at once, depending on the electronic database requirements. For example, synthetic cannabi* to 
allow for cannabis and cannabinoid.  
Inclusion and Exclusion Criteria 
Studies assessing the impact of SCs on psychological outcomes across behavioural, affective and/or 
cognitive domains were included. Methodologically, controlled administration, cross-sectional, qualitative 
studies and surveys were included; case-reports or case series and studies solely analysing case notes or 
existing databases were excluded. Studies had to be published in English, in peer-reviewed journals before 
February 2018. There was no restriction on the setting (e.g. inpatient, forensic settings, high schools). 
Study Selection and Data Extraction 
<Insert Figure 1 about here> 
Figure 1: PRISMA diagram showing the review process 
 
Results from the literature searches were exported into Endnote, a reference management software. 
Duplicate records were removed and the titles and abstracts were then screened for eligibility based on the 
inclusion criteria. The full-text of the remaining articles were then reviewed by the researcher (HA) who  
determined whether each study met inclusion criteria. Full details of the review process are shown in the 
PRISMA flow diagram (Figure 1). 
Quality Assessment 
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The Standard Quality Assessment Criteria, QualSysts (Kmet et al., 2004) was chosen to assess study quality 
as it can be applied across various study designs. The tool consists of 14 questions for quantitative studies 
and 10 for qualitative, and not all questions apply to all study designs. From the ratings given for each 
question, a summary percentage score can be produced which is then comparable across study designs. 
Two independent raters conducted the quality assessment. Where there were disagreements papers were 
discussed and ratings were jointly agreed. The quality assessment was not used to determine study 
eligibility in the review but is reported to inform the interpretation of findings. 
Results 
1661 records were identified from the database search. After duplicates were removed and titles screened, 
233 abstracts and full-text articles were reviewed. Subsequently, 216 records were excluded due to not 
meeting the review inclusion criteria (Figure 1).  
Study Description 
Table 1 shows a summary of the studies’ characteristics, including country, design, population, sample size 
and quality assessment rating. 
Overall, 17 papers were included in the study: 1 experimental study, 7 cross-sectional studies, 5 online 
surveys and 4 qualitative studies. Eight studies utilised comparison groups or conditions in their design. All 
included studies were published between 2011 and 2018 reflecting the recency of the development and use 
of these drugs.
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Table 1:  
Descriptive information and quality assessment rating for all studies included in the review 
Reference Country Population Sample size, 
total n 
Comparison 
group/condition 
QualSysts 
rating (%) 
Controlled Administration Studies 
Theunissen, et al. (2018) The Netherlands Healthy volunteers 6 Yes 89 
Cross-sectional Studies 
Altintas, et al. (2016) Turkey Psychiatric inpatients 81 Yes 86 
Blevins, et al. (2016) USA Adolescent cannabis users 252 Yes 75 
Bonar, et al. (2014) USA Substance use treatment centre 
residents 
396 Yes 75 
Clayton, et al. (2017) USA High school students 13 624 Yes 96 
Cohen, et al. (2017)  Hungary and Israel Substance use treatment centre 
residents and psychiatric 
inpatients 
122 Yes 86 
Gunderson, et al. (2014) USA Adult cannabis users 42 No 57 
Welter, et al. (2017) Germany Psychiatric inpatients 332 Yes 75 
Internet Surveys 
Barratt, et al. (2013).  Australia Users of SCs 316 No 71 
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Vandrey, et al. (2012).  Global Users of SCs 168 No 61 
Winstock, and Barratt (2013a) Global General population 14 966 No 57 
Winstock, and Barratt (2013b) Global General population 15 200 Yes 76 
Winstock, et al. (2015). 
 
Global General population 21 656 No 71 
Qualitative Studies 
Every-Palmer (2011) New Zealand Forensic inpatients 15 No 25 
Kassai, et al. (2017).  Hungary Drug rehabilitation service users 6 No 75 
Soussan, and Kjellgren (2014) Sweden Online drug forum users 254 No 75 
Van Hout and Hearne (2017) Republic of Ireland Dependent SC users 6 No 60 
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Controlled Administration Studies 
There has been one experimental study to date, where 6 healthy experienced cannabis users were each 
administered two doses of a SC compound (JWH-018 2 & 3mg) and placebo via inhalation in a within-
subjects design (Theunissen, et al. 2018, see Table 2 for details). The authors spent several years to obtain 
ethical approval for this study given the practical hazards and ethical concerns of administering SCs to 
young, healthy participants. The study is clearly underpowered and therefore generalisations from these 
findings are limited (Theunissen et al., 2018). 
The participants were given a series of questionnaires and cognitive tests and monitored for 12 hours 
following inhalation of the SC. Compared with placebo, JWH-018 significantly increased tracking errors 
when following a moving target on a screen, in both the Critical Tracking Task (CTT) and Divided 
Attention Task (DAT), indicating poorer motor performance. The SC also slowed stop-signal reaction times 
on the Stop Signal Task (SST), indicating impaired response inhibition. However, these significant 
differences were only found following a summation of the scores of the cognitive measures across all post-
drug test times, although there was no clear justification of this, lowering the quality of the study. Executive 
function, spatial memory and information processing did not show any significant differences between the 
three conditions. Further, there were no clinically significant changes recorded from physical vital signs or 
ECG patterns across the three conditions. 
Subjective ratings of feeling ‘high’ showed that participants felt more ‘high’ at one and two hours after 
administration of the low-dose SC compared to placebo, but this was not significant following the high 
dose. Subjective ‘high’ scores correlated positively with concentrations of JWH-018 in serum after both 
SC doses. The Visual Analogue Scale (VAS) also included a measure of ‘highness’ and this was 
significantly higher after the low dose compared to both the placebo and high dose. Similarly, the VAS 
composite of external perception, measuring the level of misperception of an external stimulus, was higher 
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for the low dose compared to the high. The Profile of Mood States (POMS) showed that participants 
reported greater fatigue at 5 and 12 hours after administration of the high dose compared to the placebo, 
alongside increased ratings of arousal at 12 hours following the low dose compared to both placebo and the 
high dose. 
Notably, many of the significant differences were between the 2mg dose and placebo, with fewer significant 
differences between the placebo and the 3mg dose or between the 2mg and 3mg doses. This could imply 
an inverse dose relationship. Pharmacokinetics showed serum levels of the SC were unexpectedly very low, 
had no clear dose-concentration relationship and indeed, were lower after the 3mg than the 2mg dose. This 
may have reflected the ineffectiveness of the method by which the drug was ingested as the authors report 
JWH-018 residue in the pipes  used for inhalation and post-hoc testing revealed that up to 70% of active 
drug was not inhaled. This as well as the low sample size is clearly a methodological limitation of this 
study.
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Table 2:  
Experimental study: demographic data  and outcome measures 
Reference Sample 
size (n) 
Age 
mean 
(SD) 
Gender 
% male 
(n) 
Substance 
and 
detection 
method 
Cognitive test Subjective effect questionnaires 
Information 
processing 
Motor 
performance 
Divided 
attention 
Response 
inhibition 
Executive 
function 
Spatial 
memory  
Subjective 
high 
Mood Psychedelic 
effects 
Dissociation 
Theunissen, 
et al. (2018) 
6 23.5 
(3.57) 
33.3 (2) JWH-018, 
urine and 
blood tests 
Digit symbol 
substitution 
Critical 
tracking task 
Divided 
attention 
task 
Stop 
signal task 
Tower of 
London 
Spatial 
memory 
task 
Subjective 
high rating 
on a visual 
analogue 
scale 
Profile 
of 
mood 
states 
Bowdle 
visual 
analogue 
scales 
Clinician 
administered 
dissociative 
states scale 
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Cross-Sectional Studies 
Seven cross-sectional studies were included in the review and are detailed in Table 3a. 
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Table 3a 
Cross-sectional studies: Group definitions, demographic data and outcome measures employed 
Reference Groups 
(n) 
Age mean 
(SD) 
 
Gender 
% male (n) 
Inclusion criteria Psychological outcomes 
Altintas, et al. (2016) Psychosis 
following SC 
use 
(50) 
25.9 
(5.5) 
100 
(50) 
Self-report SC use for at least 4 
months, not acute intoxication, no 
previous psychiatric diagnosis. 
 
 
Brief Psychiatric Rating Scale  
Positive and Negative Syndrome Scale 
Frontal Assessment Battery (including subscales 
of conceptualisation, mental flexibility, 
programming, sensitivity to interference, 
inhibitory control and environmental autonomy) 
Hamilton Rating Scale for Depression 
Hamilton Anxiety Rating Scale 
Schizophrenia 
(31) 
42.9 (11.6) 100 
(31) 
No personal or family history of SU 
and a diagnosis of schizophrenia 
 
 
Blevins, et al. (2016) Lifetime SC 
use 
(72) 
 
15.70 
(1.02) 
72.2 
(52) 
Self-report SC use ever  
 
Subjective effects (for those who had used SCs 
within the past 60 days, n=15) 
No lifetime 
SC use 
(180) 
 
15.87 
(0.94) 
 
 
66.7 (120) Self-report no SC use ever 
15 
 
 
Bonar, et al. (2014) 
 
Lifetime SC 
use 
(150) 
30.0 
(9.8)a*** 
 
62 
(93) 
Self-report SC use ever Beck Depression Inventory 
Global Severity Index, Paranoid ideation and 
Psychoticism subscales from the Brief Symptom 
Inventory (BSI) 
 
 
 
No lifetime 
SC use 
(246) 
37.7 
(10.2)a*** 
 
70 
(172) 
Self-report no SC use ever 
Clayton, et al. (2017) 
 
Lifetime SC 
use 
(1554) 
 57.8 
(892)b* 
Self-report SC use ever 
 
Health risk behaviours including questions on 
mental health: 
Have you ever felt sad or hopeless; seriously 
considered attempting suicide; attempted 
suicide. 
 
 
 
 
 
Lifetime NC 
only 
(4585) 
 50.8 
(2329)b* 
Self-report NC use ever and no SC use 
 
Non-use 
(9049) 
 
 50.0 
(4525)b* 
Self-report no NC or SC use ever 
Cohen, et al. (2017)  
 
SC users  
(38) 
26.57 
(7.90) 
76  
(29) 
Regular SC use on a monthly basis 
with minimal usage of at least 10 times 
in the last year. 
Beck depression inventory 
Spielberger state-trait anxiety inventory 
Computerised tasks:  
N-back task (working memory, matching of 
symbols in a 1-back or 2-back condition). 
NC users  
(43) 
26.98 
(5.37) 
53  
(23) 
NC use more than 10 times in the last 
year and no SC use in the last year. 
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Non-C users 
(41) 
25.56 
(3.03) 
54  
(22) 
No NC or SC use in the last year. The Stroop task (inhibition, naming of colours of 
words in matching and non-matching 
conditions). 
Buschke Selective Reminding task (free recall of 
16 bi-syllabic words following a diversion task). 
Gunderson, et al. (2014) Regular NC 
users who use 
SC  
(21) 
  Regular NC users who have used SCs 
ever 
Questions on subjective effects, withdrawal and 
adverse effects 
 
 
Welter, et al. (2017) 
 
SC users  
(21) 
25.6  
(6.8) 
71.4  
(15) 
Self-reported SC use Modified Positive and Negative Symptom Scale: 
9 symptom measures (persecutions, delusions, 
disorganisation, hallucinations, grandiosity, 
motor retardation, blunted affect, poor rapport 
and emotional withdrawal) 
Psychiatric diagnoses. 
 
NC users  
(26) 
31.8 (10.5) 61.5  
(16) 
Self-reported NC use 
*=p<0.05 ; **p<0.01; ***p<0.001 
a Significant differences between the two groups found, test used not reported 
b Significant differences between the three groups found with a 2 test 
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As shown, studies varied in  study populations, ranging from those with psychosis following SC use 
(Altinas et al., 2016) to adult (Cohen et al., 2017; Gunderson et al., 2014) and adolescent cannabis users 
who have ever used SCs  (Blevins et al., 2016) to high school students who have used SCs and NCs (Clayton 
et al., 2017). In addition, all studies acknowledged an overlap between NC and SC use, with those having 
used SCs having typically also using NC.   
From the studies by Bonar, Ashrafioun and Ilgen (2014) and Clayton et al., (2017) it appears that SC users 
are generally younger and more likely to be male than non-SC users. These two studies also reported on 
ethnicity and while one found that SC users were significantly more likely to be white (Bonar et al., 2014) 
the other found that they were less likely to be white (Clayton et al., 2017). However, this difference may 
be related to their different study populations: high school students (Clayton et al., 2017) compared to 
substance use disorder  patients in treatment (Bonar et al., 2014). 
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Table 3b  
Cross-sectional studies: psychological well-being and cognitive outcomes 
Reference Groups (n) Overall 
psychological 
distress 
 
Psychotic symptoms Depression Anxiety Cognitive 
Altintas, et 
al. (2016) 
  BPRSa 
 
Mean 
(SD) 
PANSSb 
overall 
Mean 
(SD) 
PANSS- 
 
Mean 
(SD) 
PANSS+ 
 
Mean 
(SD) 
HRSDc 
 
Mean 
(SD) 
HARSd 
 
Mean 
(SD) 
FABe 
 
Mean 
(SD) 
 
SC induced 
psychosis  
(50) 
 37.6 
(13.7) 
98.6 
(24.8) 
18.0 
(6.5)n** 
28.3 
(7.1) 
14.5  
(7.2) 
17.8  
(10.3)o** 
10.7  
(3.7) 
 
 
Schizophrenia  
(31) 
 32.5 
(9.1) 
91.1 
(16.5) 
22.3 
(6.0) 
 
26.0 
(5.4) 
12.0  
(7.5) 
11.4  
(9.4) 
12.1  
(4.3) 
Blevins, et 
al. (2016) 
  Paranoia 
 
% (n) 
Hallucinations 
 
% (n) 
 Nervous/Panicky 
 
% (n) 
Thought differently 
 
% (n) 
Less coordinated 
% (n) 
SC use in the 
past 60 days 
(15) 
 67  
(10) 
40 
(6) 
 53 
(8) 
67 
(10) 
67  
(10) 
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Reference Groups (n) Overall 
psychological 
distress 
 
Psychotic 
symptoms 
 Depression Anxiety Cognitive 
Bonar, et al. 
(2014) 
 GSIf 
 
 
Mean (SD) 
Paranoid ideation 
(BSIg) 
 
Mean (SD) 
Psychoticism (BSI) 
 
 
Mean (SD) 
BDIh 
 
 
Mean (SD) 
  
Lifetime SC use 
(150) 
1.26  
(0.79)p*** 
1.43  
(0.99)p*** 
1.29  
(0.94)p*** 
24.9  
(11.8)p*** 
 
  
No lifetime SC 
use (246) 
0.94 
(0.79) 
0.99  
(0.89) 
0.97  
(0.94) 
20.0  
(12.8) 
 
  
Clayton, et 
al. (2017) 
   Sadness 
 
 
%  
Suicidal 
ideation 
 
% 
Suicide 
attempt 
 
% 
  
Ever used SC 
(1554) 
 
  47.5q* 32.7q* 22.0q* 
 
  
Ever used NC 
only   
(4585) 
 
  36.8 22.2 11.1   
Non-users  
(9049) 
 
  23.5 13.3 
 
 
 
 
5.4   
20 
 
Reference Groups (n) Overall 
psychological 
distress 
 
Psychotic symptoms Depression Anxiety Cognitive    
Cohen, et al. 
(2017)  
   BDIh 
 
 
Mean  
(SD) 
SSTAIi 
 
 
Mean  
(SD) 
n(1)-
backj 
 
Mean 
(SD) 
n(2)-
backk 
 
Mean  
(SD) 
 
Stroopl  
 
 
Mean 
 (SD) 
BSRm 
 
 
Mean 
(SD) 
SC users  
(38) 
  19.97  
(10.95)r.s*** 
53.39  
(11.04)r.s*** 
75.4 
(24.34)r.s* 
67.94 
(21.37)r.s* 
 
1078.52 
(356.58)r.s* 
7.00 
(2.46)r.s* 
NC users  
(43) 
  5.76  
(4.97) 
39.24  
(9.08) 
97.25 
(3.99) 
91.54 
(7.41) 
 
869.62 
(172.43) 
10.43 
(2.57) 
Non-C users 
(41) 
 
 
 
 
 
  5.80  
(4.72) 
39.13  
(8.04) 
97.39 
(2.41) 
90.56 
(6.11) 
 
 
870.53 
(161.87) 
11.05 
(2.72) 
Gunderson, 
et al.  
(2014) 
    Anxiety 
 
 
%  
(n) 
 
Panic 
attack 
 
%  
(n) 
Trouble thinking 
clearly 
 
%  
(n) 
Fatigue 
 
 
%  
(n) 
SC users  
(21) 
   14 
 (3) 
10 
(2) 
38 
(8) 
5 
(1) 
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Reference Groups (n) Overall 
psychological 
distress 
 
Psychotic symptoms Depression Anxiety Cognitive 
Welter, et al. 
(2017) 
  Diagnosis of a psychotic disorder 
 
%  
(n) 
 
   
SC users (21)  71.4  
(15) 
 
   
NC users (26)  61.5  
(16) 
 
   
*=p<0.05 ; **p<0.01; ***p<0.001 
BPRSa = Brief Psychiatric Rating Scale 
PANSSb = Positive and Negative Syndrome Scale 
HRSDc = Hamilton Rating Scale for Depression 
HARSd = Hamilton Anxiety Rating Scale 
FABe = Frontal Assessment Battery 
GSIf = Global Severity Index 
BSIg = Brief symptom inventory 
BDIh= Beck Depression Inventory 
SSTAIi= Spielberger state-trait anxiety inventory 
n(1)-backj = n-back task, 1-back condition, % correct reported 
n(2)-backk = n-back task, 2 back condition, % correct reported 
Stroopl = The Stroop task, incongruent condition, reaction time (ms) reported 
BSRm= Buschke Selective Reminding task, words recalled reported 
n = Significant differences found between SC induced psychosis and Schizophrenia 
group, with a t-test 
o= Significant differences found between SC induced psychosis and Schizophrenia group, 
with a Mann-Whitney U 
p= Significant differences found between lifetime SC use and no lifetime SC use group, 
type of test not reported 
q = Significant differences found between ever used SC and non-user group, with a linear 
contrast 
r= Significant differences found between SC users and NC users, with an ANOVA 
s= Significant differences found between SC users and non-C users, with an ANOVA
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Psychosis and psychosis-related symptomatology: Table 3b summarises data on psychological outcomes 
across studies. Four studies assessed psychosis and psychosis-related symptomatology. Three  involved  
psychiatric populations administered validated scales (Altinas et al., 2016; Bonar et al., 2014; Welter et al., 
2017), with one of these also including a clinical diagnosis (Welter et al., 2017). The fourth study, asked 
SC users about a range of subjective effects following use, including psychosis-related experiences (Blevins 
et al., 2016). Participants then had to rate the frequency of with which specific effects were experienced. 
Bonar et al., (2014) found that amongst individuals in residential substance use disorder (SUD) treatment, 
those with SC lifetime use had statistically significant higher scores than those with no history of SC use 
in  psychological distress, paranoid ideation and psychoticism as measured by the Brief Symptom Inventory 
subscales.  .  
Welter et al., (2017) reported that 71.4% of their sample of inpatient psychiatric patients who used SCs 
were diagnosed with a psychotic disorder, compared to 61.5% of NC users. Further, positive symptoms 
including persecutions, delusions, disorganisation and hallucinations, as assessed via a modified version of 
the PANSS, were experienced by a higher proportion of SC users than NC users. Negative symptoms, 
including motor retardation, blunted affect and emotional withdrawal, were, in contrast, experienced by a 
higher proportion of NC users than SC users. Statistical analyses were not carried out on these data therefore 
it is unclear if these differences are significant. The authors also assessed severity of symptoms, and their 
findings suggested that amongst psychiatric patients SC users experience significantly less severe negative 
symptoms than NC users (p=0.026). There was no significant difference in the severity of positive 
symptoms between SC and NC users. 
Altinas et al., (2016) used the full PANSS measure and similarly found that patients who developed 
psychosis following a history of SC use had significantly fewer negative symptoms compared to those with 
a diagnosis of schizophrenia but no history of SC use. A sub-group analysis was conducted looking at older 
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(>43 years) and younger (43 years) non-SC users separately. There was a significant difference in negative 
symptoms for both groups compared to SC users of all ages who developed psychosis, however these effects 
are in different directions. Those patients with no history of SC use over the age of 43 experience fewer 
negative symptoms than SC users and those under the age of 43 experiencing more.  Similarly to Welter et 
al., (2017), levels of positive symptoms showed no significant group differences. 
From the single-questions about specific subjective effects, Blevins et al., (2016) found that 67% of their 
sample had experienced paranoia and 40% hallucinations ‘at least some of the time’ following SC use. 
Depression.  was assessed in four studies. Three of these used various validated scales (Altinas, et al., 2016; 
Bonar et al., 2014; Cohen et al., 2017); the other used single questions (Clayton et al., 2017) about ever 
experiencing (yes/no) feeling sad, having suicidal thoughts or attempting suicide. From these questions, 
Clayton et al., (2017), found significantly higher reports of experiencing these symptoms only in those who 
had ever used SCs compared to those who had never used any type of cannabis. In addition, two studies 
found significantly higher scores on depression measures for SC users compared to non-SC users (Bonar 
et al., 2014) and non-cannabis users (Cohen et al., 2017). In contrast, Altinas et al., (2016) found no 
significant difference in depression scores between those who have developed psychosis with a history of 
SC use when compared to participants with a diagnosis of schizophrenia and no history of SC use. 
Anxiety. Anxiety scales were administered in two studies (Altinas et al., 2016; Cohen et al, 2017). Altinas 
et al., (2016) found significantly higher scores in anxiety for participants with psychosis following SC use 
compared to patients with schizophrenia who had no illicit substance use history. These differences 
remained significant for patients over the age of 43, with anxiety being significantly higher in SC users. 
Conversely, compared to those under 43 years, anxiety appeared to be lower in SC users, however this was 
a non-significant difference. Cohen et al., (2017) found significantly higher anxiety scores for SC users 
compared to both NC users and non-cannabis user, however no comparison was made of age groups. 
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Cognitive tasks. Two studies administered cognitive tasks including tests of executive function, inhibition 
and long-term memory (Altinas et al., 2016; Cohen et al., 2017). Altinas et al., (2016) administered the 
Frontal Assessment Battery (FAB) to investigate differences in executive function with subscales of mental 
flexibility, programming, sensitivity to interference, inhibition control and environmental autonomy. They 
found no significant differences on any of the subscales between patients with psychosis following SC use 
and those with a diagnosis of schizophrenia. However, Cohen et al., (2017) found SC users to be 
significantly impaired in working memory, cognitive inhibition and long-term memory compared to NC 
users and non-users as measured by the n-back task (working memory), the Stroop task (response 
inhibition) and Buschke Selective Reminding task (BSRT; episodic memory) respectively, as defined in 
Table 3a. Specifically, the authors found significantly lower accuracy for SC users compared to NC users 
and non-cannabis users on  the n-back and Stroop task; longer reaction times on the Stroop task (across 
matching and non-matching conditions); and  significantly fewer words recalled on the BSRT task. The 
authors did note, however, that the SC user group had significantly fewer years of education compared to 
the NC users and non-cannabis users and  this could have contributed to the group differences  (Cohen et 
al., 2017). 
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Internet Surveys 
Details of the 5 internet surveys, with information from a total of 3640 SC users, are given in Table 4. Both 
psychological and physical health symptoms have been reported as these are increasingly acknowledged to 
be inherently linked. These surveys do not employ validated measures but provide a useful overview of 
psychological effects and complications related to SCs through respondents indicating yes or no to different 
experiences. As seen in Table 4, the data suggests SC users responding to internet surveys tend to be 
predominantly male and in their mid-twenties.  
A range of psychological and physical acute effects have been documented through these surveys. The most 
common of these, anxiety or panic were reported by 14% - 83% and breathlessness by 38% - 57% of 
participants. However, these ranges are so broad as to be relatively meaningless. Three surveys found the 
effects of SCs generally lasted for 1-2 hours (Barratt et al., 2013; Vandrey et al., 2012; Winstock and 
Barratt, 2013b). One survey compared effects between SC and NC users (Winstock and Barratt, 2013b). 
This showed significantly greater intensity of paranoia and significantly lower intensity of sedation, 
increased appetite and impaired memory reported after SC use compared to NC use. 
Three of these studies utilise data from the Global Drug Survey which is run annually (Winstock and 
Barratt, 2013a, 2013b; Winstock et al., 2015). Both papers published in 2013 rely on data from the 2011 
survey and therefore there is overlap in these findings.  Although termed a ‘global survey’ the data 
generated tends to be from industrialised countries rather than low income countries.
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Table 4  
Internet surveys: sample size and population, demographics of the sample, psychological and physical symptoms reported 
Reference Sample size SC 
users 
Inclusion 
criteria 
Median Age 
(IQR) 
Gender % male 
(n) 
Psychological symptoms reported Physical symptoms reported 
 
Barratt, et al. (2013).  316 Australian 
residents, over 
18, who 
reported SC 
use on one 
more prior 
occasions. 
27  
(23 - 34) 
77  
(243) 
Dissociation (22%) 
Paranoia (18%) 
Panic (14%)  
Depression (4%) 
Psychosis (4%) 
Decreased motor coordination 
(28%) 
Dizziness (20%) 
Headache (18%) 
Slurred speech (14%) 
Nausea and vomiting (9%) 
 
Vandrey, et al. (2012).  168 Ever used SC  83  
(139) 
Hallucinations (28%) 
Nervous/anxious (54%) 
Paranoia (54%) 
Trouble remembering (64%) 
 
Heavy/sluggish (63%) 
Vomited (10%) 
Winstock, and Barratt 
(2013a) 
 
 
23  SC users who 
sought 
Emergency 
Medical 
Treatment in 
the last 12 
months 
  Panic and anxiety (82.6%) 
Paranoia (56.5%) 
Feeling scared (52.2.%) 
Seeing things (47.8%) 
Extreme agitation (34.8%) 
Hearing things (30.4%) 
Aggression (17.4%) 
 
Breathing difficulties (56.5%) 
Very sweaty (52.2%) 
Chest pain (52.2%) 
Unable to talk (39.1%) 
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Winstock, and Barratt 
(2013b) 
 
 
980  Use of SCs in 
last 12 months 
 
23  
(19 - 28) 
79.6  
(758) 
Paranoiaa,*** 
Sedationb,*** 
Increase in appetiteb,*** 
Impairment in memoryb,*** 
 
 
Winstock, et al. 
(2015). 
 
2176 
 
SC use in the 
last year 
25  
(20 - 34) 
76.5  
(1554) 
n=21 (sought EMT) 
Panic and anxiety (81%) 
Paranoia (61%) 
Scared (61.9%) 
Agitation (47.6%) 
Auditory hallucinations (33.3%) 
Visual hallucinations (33.3%) 
Mood problems (28.6%) 
Aggression (9.5%) 
 
n=21 
Breathlessness (38.1%) 
Sweating (38.1%) 
Chest Pain (33.3%) 
Unable to talk (28.6%) 
Seizure /fits (19.0%) 
Bladder problems (9.5%) 
*=p<0.05 ; **p<0.01; ***p<0.001 
a = In comparison to NC users (n=975) significantly higher intensity 
b = In comparison to NC users (n=975) significantly lower intensity
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Qualitative Studies 
Four qualitative studies were included in the review and these are summarised in Table 5. They focus on 
the experiences of using SCs (Kassai et al., 2017),  developing SC dependence (Van-Hout and Hearne, 
2017), adverse effects of SC use (Soussan and Kjellgren, 2014) and the interaction with psychosis (Every-
Palmer, 2011).   
A range of psychological effects were reported following consumption of SCs. Some quotes from the papers 
illustrating these effects are included below: 
Anger: “Warm feelings, feel brilliant, but then when that feeling goes away, bad. Start feeling angry….” 
(Van-Hout and Hearne, 2017). 
Paranoia: “I can’t touch it, it makes me really paranoid… I felt that something bad was leaping out at me” 
– Male, occasional SC use (Every-Palmer, 2011). 
Anxiety: “It made me feel like my world was closing in. It made me feel anxious and worried and my heart 
was pounding.” – Male, occasional SC use (Every-Palmer, 2011). 
Memory difficulties: “I tried watching Family Guy during intoxication, but the whole time I forgot what the 
episode was about.” (Soussan and Kjellgren 2014). 
Emotionally numb: “the drug totally distorted my personality, it turned myself inside out… it made me 
blunt, and switched off my brain" - 23-year-old male. (Kassai et al., 2017). 
Mood changes: “When I smoked I was wallowing in self-pity, I felt sorry for myself, I was alone, I didn’t 
care about anybody else, I hated everyone" – 20-year-old male. (Kassai et al., 2017). 
Two papers reported themes about the unpredictability of both the physical and psychological effects of 
SCs (Kassai et al., 2017; Soussan and Kjellgren, 2014). In addition, two papers assessed effects across 
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different time points of use: acute intoxication, hangover, dependence and withdrawal (Kassai et al., 2017; 
Van-Hout and Hearne, 2017). For acute intoxication, frequent symptoms reported were tachycardia and 
respiratory difficulties, nausea and dizziness, warm and happy feelings, agitation, restlessness and fear and 
paranoia (Kassai et al., 2014; Van Hout and Hearne 2017). The most common symptoms reported during 
the hangover period were sluggish and dull feelings, tiredness and dehydration (Kassai et al., 2014). 
Dependence and withdrawal were characterised by memory and concentration impairments, mood swings, 
disconnection, aches and pains, anxiety, agitation and paranoia (Kassai et al., 2017; Van-Hout and Hearne 
2017). In addition, Van-Hout and Hearne (2017) elicited a theme on self-detoxification attempts where 
participants described suicidal ideation and physical symptoms such as diarrhoea, insomnia and sweating.  
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Table 5  
Qualitative studies: sample size and population, the method of data collection and analysis, the type or brand of SC, psychological and other outcomes reported 
Reference Sample size SC 
users 
Population Method of data 
collection and 
analysis 
 
Type or brand 
of SC 
Psychological effects Other effects 
Every-Palmer 
(2011) 
15 
Male 100% 
 
Forensic inpatients 
identified by staff as 
having relapsed in the 
context of SC use. 
 
Semi-structured 
interviews 
 
Thematic analysis 
Aroma, 
Kronic, 
Skunk, 
Dream, Spice 
Pronounced anxiety 
Psychotic relapse 
Paranoia 
 
Shaking  
Dizzy 
Heart pounding 
Kassai, et al. (2017).  6 
Male 100% 
20-27  
Drug rehabilitation 
Self-identified SC 
users with problematic 
use for at least 2-6 
years, abstinent for the 
past 1 month. 
Semi-structured 
interviews 
 
Interpretative 
phenomenological 
analysis 
 
 
 
 
 
 
 Paranoia 
Relaxation 
Difficulty socialising 
Increased egoism 
Self-neglect 
Switch off brain 
Inability to sleep 
Feeling under control 
Sweating 
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Soussan, and 
Kjellgren (2014) 
254  
 
Online drug forum 
users from one online 
forum 
Internet posts on an 
online forum 
 
Thematic analysis 
 Sluggish/dull 
Disconnected and emotionally 
numb 
Fear and paranoia 
Panic attacks 
Disorientation 
Derealisation 
Mood swings 
Memory impairment 
Concentration difficulties  
 
Nausea and dizziness 
Tachycardia and 
breathing difficulties 
Dehydration 
Muscle pain and 
tension 
 
Van Hout and 
Hearne (2017) 
6 SC dependent 
users 
50% male 
Dependent SC users as 
measured by the 
Severity of 
Dependence scale 
(scores above 7).  
Semi-structured 
interviews 
 
Empirical 
Phenomenological 
Psychological five-
step method 
 
5f-AKB48 
5F-PB-22 
Agitation and restlessness 
Fear  
Paranoia 
Aggression 
Severe dissociation 
 
Chest pain 
Aches and pains  
Palpitations 
Nausea 
Sweating 
Vomiting 
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Discussion 
Overview 
In this review we aimed to summarise the current evidence about the psychological effects of SC use. 
Previous reviews of the literature have focused on papers with small samples such as case-reports or case-
series and research using information from poison hotline databases and toxicology reports (e.g. Brewer 
and Collins, 2014; Papanti et al., 2013). The current review aimed to outline the existing literature outside 
of these formats and this  highlighted four main types of research methodology: controlled administration, 
cross-sectional, internet surveys and qualitative studies.  
Unsurprisingly, there was a dearth of rigorous, peer-reviewed experimental research with controlled 
administration of SCs, with only one pilot study currently published (Theunissen et al., 2018). This was the 
first controlled study whereby a SC was administered with the intention of monitoring the cognitive and 
subjective effects of the drugs. Previous attempts have relied on self-experimentation from authors 
(Auwarter et al., 2009) or administration for developing technology to detect SCs in urine (Teske et al., 
2010).   
Acute SC intoxication can potentially result in impaired motor functioning, attention and response 
inhibition, but not have an effect on other executive functions, spatial memory and information processing 
(Theunissen et al., 2018).  Interpretation of this study is hampered, however, given that serum levels of the 
drug were low and not dose-related, and the study lacked statistical power.  The internet surveys provide a 
wealth of retrospective self-report data of the acute effects of SC use, with panic, anxiety, paranoia and 
breathlessness being reported most frequently (Barratt et al., 2013; Vandrey et al., 2012; Winstock and 
Barratt, 2013a; Winstock and Barratt, 2013b and Winstock et a., 2015). Similarly, the qualitative research 
provides a phenomenological account of the acute effects, with paranoia, fear and anxiety being mentioned 
in all of the studies (Every-Palmer, 2011; Kassai et al., 2017; Soussan and Kjellgren, 2014 and Van Hout 
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and Hearne, 2017). Given the diversity of methods used, and the limitations inherent in each of these, it is 
perhaps surprising that the acute effects reported are fairly consistent.  
Individuals classified as SC users were found to have significant impairment in working memory, inhibition 
and long-term memory compared to NC and non-cannabis users (Cohen et al., 2017). SC users have been 
found to experience more anxiety, paranoia, psychoticism and depressive symptomatology compared to 
NC users and non-users (Bonar et al., 2014; Clayton et al., 2017; Cohen et al., 2017). In addition, SC users 
experiencing psychosis have been found to experience less severe negative symptoms and more anxiety 
than those with schizophrenia without co-morbid SC use (Altinas et al., 2016). Welter et al., (2017) found 
significantly greater positive symptoms and fewer negative symptoms in psychiatric patients using SC 
compared to those using NC only. 
Methodological Limitations 
This review highlights a range of methodological limitations with current published studies. The paucity of 
controlled human experimental research is notable. In the available uncontrolled research we cannot 
objectively know whether SC users are under the influence of any psychotropic drug. The controlled 
administration study is the only one where intoxication has been guaranteed (Theunissen et al., 2018). 
However, as they recruited a very small sample size due to ethical and practical limitations, this 
considerably limits the generalisability of the findings. 
The cross-sectional research is variable in its quality, with a mean quality assessment rating of 78.5%. 
Studies ranged from using validated measures to less reliable, single-questions to evaluate psychological 
effects of SC use. In addition, the inclusion of participants always relied on retrospective self-report of SC 
use which introduces recall bias, whereby data may be unreliable. Furthermore, this method means these 
studies provide little information about the impact of specific compounds. No study blinded researchers to 
study group introducing further bias into the results and lowering the quality rating. Limited adjustments 
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for confounding factors were made across these studies, apart from an acknowledgement of age and 
education level in two studies (Altinas et al., 2016; Cohen et al., 2017 respectively). It is likely that there 
will be pre-existing differences between those who do and do not use SC that may contribute to mental 
health and cognitive differences, such as concomitant effects of other drug use, that are not accounted for 
by the current cross-sectional research. 
The mean quality rating of the internet surveys was 67.2%. A methodological limitation across all included 
surveys, bringing down their ratings, was the reliance on uncontrolled and purposive sampling. The Global 
Drug Survey is widely advertised through magazines and newspapers internationally. This type of sampling 
creates a response bias, whereby those who take part are more likely to have a greater interest in or 
experience with drugs and may not be representative of the wider general population. Two surveys focus 
specifically on SC users and recruitment relied on advertisement in internet forums and on social media 
platforms where SCs are discussed, again inviting further bias (Barratt et al., 2013; Vandrey et al., 2012). 
The samples are likely to over-represent those who have an extensive drug use history and are more engaged 
with online discussion groups, therefore these findings may not be representative of the wider populations 
of SC users. All the surveys rely on retrospective self-reporting of symptoms during the acute phase of 
taking SCs which introduces recall bias into the results, making them less reliable. None of the included 
surveys attempt to capture specific compounds used therefore there is no way to attribute the effects 
reported to a specific form of SC.  
The mean quality rating for the qualitative studies was 58.8%. Only two of the studies used verification 
procedures to establish the credibility of the analysis (Kassai et al., 2017; Soussan & Kjellgren, 2014) and 
none of the studies incorporated reflexivity bringing down the scores. In particular, one study undertaken 
in an inpatient setting relied on selection by staff and interviewing by a staff member, this may have had an 
influence on the participants' willingness to report the effects fully and honestly (Every-Palmer, 2011). In 
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addition, this study relied on interviews being recorded by hand and then made into longer notes once 
completed as participants declined audio recording. This will have introduced bias as what is recorded is 
shaped by what is remembered by the interviewer, which was not acknowledged in the paper. 
Sampling is a key issue across the cross-sectional, survey and qualitative research. The most common 
approach is purposive sampling which introduces bias into the results, again reducing the generalisability 
of findings. There is clearly a difficulty in finding any individuals who only use SCs, as polydrug use is the 
norm and this potentially entails complex drug interactions. Where there are comparisons made with NC 
users, the frequent overlap between the use of the two drugs creates difficulty in associating effects with 
SC independently. In addition, research in specific vulnerable populations is limited, perhaps due to 
difficulties in sampling in these groups. We found only one study conducted in a forensic hospital setting 
(Every-Palmer, 2011) and no published research with homeless or prison populations where SC use is 
prevalent. 
Another limitation of current research is the lack of biological confirmation of SC use from immunoassays 
of bodily fluids. The technology for this is not yet widely available and only one study discusses serum 
levels of SCs (Theunissen et al., 2018). Instead, studies are dependent on self-reporting of SC use and this 
reduces reliability as it introduces recall bias, especially important when the study retrospective memory of 
effects while the person is intoxicated with a memory impairing drug like SC and NC . In combination, the 
heterogeneity of the 179 SCs available, and the insufficient data on specific compounds or their doses in 
each study further limits the interpretation of findings. Only the controlled administration study (Theunissen 
et al., 2017) involved a specific SC compound. Van Hout and Hearne’s (2017) study was the only other 
paper that specified certain compounds. However, the authors simply stated they recruited participants who 
said they use 5f-AKB48 and 5F-PB-22. However, no biological or other evidence of their use of these 
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specific drugs was gathered. Therefore, from only one study are we able to reliably draw conclusions about 
a specific compound, JWH-018 (Theunissen et al., 2018).  
Review Limitations 
The research reviewed is varied both in the research questions posed and the study population examined. 
A breadth of research questions have been collated, integrating findings of acute effects, from controlled 
administration and self-report data, with longer-term effects from psychological measures and cognitive 
tasks taken from those self-identified as SC users. Different studies also involved markedly different 
populations, from cannabis users in the general population (Blevins et al., 2016; Cohen et al., 2017; 
Gunderson et al., 2014) to those with diagnoses of serious mental illness (Altinas et al., 2016; Every-Palmer 
2011) to dependent users and those engaged with drug treatment (Kassai et al., 2017; Van Hout and Hearne 
2017) to high school students (Clayton et al., 2017). This clearly limits the integration of the findings across 
studies.  
The majority of the reviewed studies do not differentiate between the psychological effects of SCs 
according to different usage patterns, which again limits the conclusions we can draw. Only two of the 
included studies specifically look at problematic (Kassai et al., 2017) and dependent (Van Hout and Hearne, 
2017) users giving more useful information about this sub-group of the SC user population. In addition, 
two cross-sectional studies specify a certain level of use to be categorised as an SC user (Altinas et al., 
2016; Cohen et al., 2017). Other than this, the research does not distinguish between those who have tried 
SCs once and those who use with differing degrees of regularity. In these cases, it is difficult to determine 
what  psychological effects are related to the chronic, prolonged use of SCs.  
In addition, is important to note that these studies come from a time period when SCs have undergone 
several changes to their legal status and classification internationally. Governments across the globe have 
attempted to stem distribution of SCs through increased legislation such as the Novel Psychoactive 
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Substances Act 2016 in the UK. This now makes it an offence to produce, supply or possess with intent to 
supply, any substance intended for human consumption that is capable of producing a psychoactive effect.  
This will have impacted on their production and availability of different compounds and the market 
continues to evolve today. Therefore, the review may not accurately represent the profile of psychological 
effects of SCs that are predominantly in circulation at the moment.  
Clinical and Research Recommendations 
Given the diversity of available SC compounds, the constantly changing composition even within brands, 
difficulties with detection and the limited available evidence highlighted from this review, making specific 
clinical recommendations is currently problematic. It is evident that SC use is becoming increasingly 
popular in some populations and actions taken by governments to reduce their availability appear 
ineffective. It is therefore imperative for clinicians working with at-risk populations - including homeless 
and prison populations - to be aware of SC use and its potential consequences in order to provide support 
and advice to users around the impact and risks  it use can have. 
Given that SC use is a relatively recent phenomenon it is apparent that it is an under-researched area. 
However, the continual growth of this market suggests that SCs will continue to be widely available via the 
internet, and therefore pose an ongoing risk. More rigorous evidence on the effects of SC use is needed to 
inform clinical decisions and policy making. It is key for clinicians to be involved in the research process 
going forward, to provide information and access to SC users to improve the existing evidence base.  
Research methods need to be improved with the inclusion of biological confirmation of use, through testing 
samples, and an attempt to identify the specific compound used in order to inform the conclusions drawn. 
There is a need for more controlled lab studies looking at the acute effects of SC use. However as 
Theunissen et al., (2018) found, ethical approval for research with a large sample size is currently difficult 
to achieve due to the risks involved with administering SCs to participants. More naturalistic studies 
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prospectively monitoring the acute effects for users in their own homes may be  possible as has been done 
in those using different natural cannabis varieties (for review see Curran et al, 2016).,  
Cross-sectional research could be improved with larger samples and therefore higher powered studies to 
assess differences in psychological outcomes between groups of users and non-users. This research should 
attempt to adjust for the many potential confounding factors that may account for some of the group 
differences observed. Clearer categorisation in research of regular users compared to one-off users would 
also prove useful in mapping the prolonged psychological effects of SC use. There have been no 
longitudinal studies, following up large cohorts to map the effects of SC use prospectively over time, to 
date. Studies of this kind will prove useful in the future. 
Conclusions 
SC use is a growing concern and there is an urgent need to bring together current knowledge to inform 
users, healthcare professionals and policymakers. This review integrates findings from a range of sources 
to evidence what we understand about the impact of SCs at the moment. It is evident that SC use can result 
in a range of psychological outcomes as well as SC users being more impaired in behavioural, affective and 
cognitive domains, compared to NC and non-users. It also highlights the difficulties of capturing the effects 
of these compounds due to their ever-increasing variety and potential dangerousness. The latter has limited 
the possibility of large-scale controlled experimental research. Going forward, novel research methods with 
larger samples are needed  if we are to better understand the psychological consequences of synthetic 
cannabinoids 
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